

REMARKS

Status

Claims 1-6, 11-14 and 27-31 will be pending in this application upon entry of the present amendments. Support for the present amendments is inherent in the specification. No new matter will be added upon entry of the present amendments.

Discussion


Applicants' representative, Jing Belfield, thanks the Examiner for helpful and courteous telephone conversation held on April 13, 2004. Examiner indicated that the previous amendments with regard to the treatment of specific diseases would be considered in view of the references if a Request for Continued Examination is filed. Applicants respectfully request consideration and entry of claims 27-31.

The rejection of the methods of treatment of inflammation in general has been obviated by appropriate amendment. Withdrawal of this rejection is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Date: April 14, 2004

Respectfully submitted,



Jing Belfield, Ph.D.
Agent for Applicants
Registration No. 45,914

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791 (phone)
(609) 252-4526 (fax)